Learn about mAbs

Aims and scope

mAbs is a multidisciplinary, open access journal dedicated to the art and science of antibody research and development.

The journal has a strong scientific and medical focus but serves a broad readership, including specialists in technology transfer, legal issues, investment, planning and the regulation of therapeutics.

mAbs covers a range of topics, including:

Engineering and selection of antibody therapeutics, including antibody-drug conjugates, multispecific andtibodies, and single-domain antibodies
Machine learning and artificial intelligence applications
Non-clinical studies of antibodies, such as mechanism of action studies, safety and efficacy studies in animals
Manufacturing and formulation
Regulatory review of antibody therapeutics
Post-approval topics, such as markets

mAbs accepts original research papers, brief reports, short communications, reviews, perspectives, commentaries, meeting reports, and article addenda.

The journal operates a single-anonymized peer review policy.

*Please note that mAbs converted to a fully Open Access journal beginning with Volume 12 (2020). The 2009-2020 volumes will be free to access from 1 January 2021 .

Journal metrics

Usage

1.3M annual downloads/views

Citation metrics

5.6 (2023) Impact Factor
Q1 Impact Factor Best Quartile
5.8 (2023) 5 year IF
10.7 (2023) CiteScore (Scopus)
Q1 CiteScore Best Quartile
1.230 (2023) SNIP
1.702 (2023) SJR

Speed/acceptance

5 days avg. from submission to first decision
32 days avg. from submission to first post-review decision
14 days avg. from acceptance to online publication
39% acceptance rate

Understanding and using journal metrics

Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.

We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.

For more details, please read the Author Services guide to understanding journal metrics.

Journal metrics in brief

Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).

Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.

Citation Metrics

Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.

Speed/acceptance

From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.

For more details on the data above, please read the Author Services guide to understanding journal metrics.

*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus

Editorial board

Editor-in-Chief
Janice M. Reichert - The Antibody Society, Inc., Framingham, MA, USA [email protected]

Associate Editor
Alain Beck - Centre d'Immunologie Pierre Fabre, St Julien-en-Genevois, France
Alexey A Lugovskoy - Diagonal Therapeutics, Cambridge, MA, USA

Assistant Editors

Patrick Bulau - Roche Diagnostics GmbH, Penzberg, Germany
Partha S. Chowdhury – Janssen Biopharmaceutical, Spring House, PA, USA
Marc Damelin - Mersana Therapeutics, Cambridge, MA, USA
Nimish Gera - Mythic Therapeutics, Waltham, MA, USA
Nathan Higginson-Scott - Seismic Therapeutic, Cambridge, MA, USA
Nick Hutchinson - FUJIFILM Diosynth Biotechnologies, Billingham, UK
Konrad Krawczyk - Natural Antibody, Szczecin, Poland
Pin-Kuang Lai - Stevens Institute of Technology, Hoboken, New Jersey, USA
Sandeep Kumar - Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
Jonathan Sockolosky - Genentech, South San Francisco, CA, USA
Feng Yang - Genentech, South San Francisco, CA, USA
Honghui Zhou - Janssen Research & Development, LLC, Spring House, PA, USA
Li Zhou - AbbVie, Worcester, MA, USA
Zhaohui Sunny Zhou - Northeastern University, Boston, MA, USA

Editorial Board
Taruna Arora - Bristol Myers Squibb., Redwood City, CA, USA
Andrew Bradbury - Specifica Inc, Santa Fe, NM, USA
Pavel V. Bondarenko - Amgen, Thousand Oaks, CA, USA
Paul J. Carter - Genentech, Oceanside, CA USA
Steven Chamow - Alira Health Boston, LLC, Framingham, MA, USA
Daniel Christ - Garvan Institute of Medical Research, Syndey Australia
Stefan Dübel - Technische Universität Braunschweig, Braunschweig, Germany
Charles Dumontet - Université de Lyon, Lyon, France
William (Jonny) Finlay - UltraHuman Limited, Edinburgh, UK
Patrick Garidel - Boehringer Ingelheim Pharma GmbH & Co KG, Innovation Unit, Biberach, Germany
Iqbal S. Grewal - Janssen, Spring House, PA, USA
Hiten Gutka - Bristol Myers Squibb, New Brunswick, NJ, USA
Jagath Reddy Junutula - Aarvik Therapeutics, Fremonth, CA, USA
Christian Klein - Roche Glycart AG, pRED, Zürich, Switzerland
Roland E. Kontermann - Universität Stuttgart, Stuttgart, Germany
Marie-Paule Lefranc - Université Montpellier II, Montpellier, France
John McCafferty - Maxion Therapeutics, Cambridge, UK
Dario Neri - Swiss Federal Institute of Technology Zürich, Zürich, Switzerland
Paul Parren - LAVA Therapeutics, Utrecht, The Netherlands
Andreas Plückthun - University of Zürich, Zürich, Switzerland
E. Sally Ward - University of Southampton, Southampton, UK
Hervé Watier - Université François-Rabelais/CNRS, Tours, France
Jan van de Winkel - Genmab, Copenhagen, Denmark
K. Dane Wittrup - Massachusetts Institute of Technology, Cambridge, MA, USA
Clive Wood - Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany
Thierry Wurch - Evotec, Lyon, France
Jianlin (Jim) Xu - Bristol-Myers Squibb, Devens, MA, USA

Abstracting and indexing

mAbs is abstracted/indexed in:

DOAJ
EBSCOhost
- Biological Abstracts (Online)
Elsevier BV
- EMBASE
- Scopus
National Library of Medicine
- PubMed/MEDLINE
Thomson Reuters
- Biological Abstracts (Online)
- BIOSIS Previews
- Biotechnology Citation Index (Online)
- Science Citation Index Expanded
- Web of Science

Open access

mAbs is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.

Why choose open access?

Increase the discoverability and readership of your article
Make an impact and reach new readers, not just those with easy access to a research library
Freely share your work with anyone, anywhere
Comply with funding mandates and meet the requirements of your institution, employer or funder
Rigorous peer review for every open access article

Article Publishing Charges (APC)

To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.

Use our APC finder to calculate your article publishing charge

Advertising information

Would you like to advertise in mAbs?

Reach an engaged target audience and position your brand alongside authoritative peer-reviewed research by advertising in mAbs.

Explore advertising solutions

Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .

Citation search

Jump to section

About this journal

Aims and scope

Journal metrics

Understanding and using journal metrics

Journal metrics in brief

Citation Metrics

Speed/acceptance

Editorial board

Abstracting and indexing

Open access

Why choose open access?

Article Publishing Charges (APC)

Advertising information

Would you like to advertise in mAbs?

Ready to submit?

Information for

Open access

Opportunities

Help and information

Citation search

Your download is now in progress and you may close this window

Login or register to access this feature

About this journal

Aims and scope

Journal metrics

Understanding and using journal metrics

Journal metrics in brief

Citation Metrics

Speed/acceptance

Editorial board

Abstracting and indexing

Open access

Why choose open access?

Article Publishing Charges (APC)

Publication details

Related websites

Advertising information

Would you like to advertise in mAbs?

Ready to submit?

Information for

Open access

Opportunities

Help and information

Keep up to date